Pharmacogenetic Interactions Between ABCB1 and SLCO1B1 Tagging SNPs and the Effectiveness of Statins in the Prevention of Myocardial Infarction

• DOI: 10.2217/pgs.10.81
• Publication Date: 2010-08-12T12:54:34Z
• Authors: Bas JM Peters; Andrei S Rodin; Olaf H Klungel; Cornelia M van Duijn; Bruno H Ch Stricker; Ruben van‘t Slot; Anthonius de Boer; Anke-Hilse Maitla...
• Keywords: SLCO1B1

Genetic variability within the SLCO1B1 and ABCB1 transporter genes has been associated with modification of statin effectiveness in cholesterol management.We conducted a case-control study using population-based registry pharmacy records linked to hospital discharge records. Within hypercholesterolemic cohort, we included 668 myocardial infarction cases 1217 controls.We tested 24 tagging SNPs found two (rs3789244, p = 0.01; rs1922242, 0.01) interact treatment. In addition, nonsignificant haplotype-treatment interaction (p 0.054). The odds ratio for subjects homozygous SLCO1B1*1A was 0.49 (95% CI: 0.34-0.71) compared 0.31 0.24-0.41) heterozygous or noncarriers *1A allele.This is first demonstrate that common genetic statins prevention clinical outcome, infarction.